PharmaMar SA Earnings Call Signals Growth Momentum

Pharma Mar SA ((ES:PHM)) has held its Q4 earnings call. Read on for the main highlights of the call.

PharmaMar SA’s latest earnings call struck an upbeat tone, with management highlighting a powerful rebound in both operations and finances. Revenue growth of 27% year on year, a fivefold jump in EBITDA, and strong cash generation set a confident backdrop, even as executives acknowledged FX headwinds, competitive pressures, and execution risks around European launches.

Strong Top-Line Growth

PharmaMar delivered 27% revenue growth in 2025, underscoring renewed commercial momentum across its portfolio. Sales rose 20%, royalties climbed 4%, and licensing revenues surged 66%, showing that both core products and deal-making contributed meaningfully to the top line.

Major Profitability Improvement

Profitability improved sharply, with EBITDA reaching about €68 million, roughly five times the prior year’s level. Net income jumped 187% to €75 million, signaling strong operating leverage as revenue growth outpaced the rise in expenses.

Cash Generation and Balance Sheet Strength

Operating cash flow came in at €53 million, reinforcing the quality of earnings and supporting future growth investments. Cash and financial investments closed the year at €168 million, while net debt stayed broadly in line with 2024 despite €34 million spent on share buybacks.

Regulatory and Commercial Milestones for Zepzelca

Zepzelca hit several key milestones, including U.S. approval in October 2025 for first-line maintenance use and a green light in Switzerland. In Europe, the regulatory dossier is under review, with an EMA opinion expected in the first quarter of 2026 and initial country launches targeted for the second half of 2026.

Commercial Momentum for Key Products

Commercial trends for core brands were encouraging, with Zepzelca showing early traction in Switzerland and a 31% growth rate under France’s early-use model. Yondelis remained resilient despite generics, with raw material sales to partners up 20%, U.S. royalties more than doubling, and European unit sales advancing about 4%.

Clinical Pipeline Progress and Upcoming Catalysts

The pipeline advanced on multiple fronts, with pivotal trials LAGOON and SaLuDo progressing on schedule and setting up key readouts from 2026 onward. Early-stage assets PM54 and PM534 also moved forward, including an immunotherapy combination trial for PM54 expected to start in the first half of 2026 and a planned PM534 expansion in the second half.

Decline in U.S. Zepzelca Royalties

Not all trends were positive, as U.S. royalties from Zepzelca fell 12% year on year in 2025. Management cited a roughly 7.5% negative euro–dollar FX impact and the arrival of a new competitor as the primary drivers behind this decline.

Pricing and Reimbursement Uncertainty in Europe

European pricing and reimbursement remains a swing factor, with negotiations such as those in Switzerland still in progress and stretching into mid-2026. This uncertainty could delay or cap early revenues in Europe even if EMA approval for Zepzelca arrives on the expected timetable.

Exposure to Partner Disclosures and Limited Transparency

The company’s heavy reliance on partners like Jazz, J&J and Merck limits what management can share about some commercial details. Inability to disclose partner forecasts, inventory levels or certain sales metrics adds an extra layer of uncertainty for investors trying to model future performance.

Generic Competition and Patent/Market Risk

Yondelis is already facing six approved generics in Europe, creating ongoing pressure on pricing and market share. The potential arrival of generics in the U.S. remains a further unknown, representing a downside risk to future royalty income despite the recent strength in that business.

Rising Commercial Costs and Near-Term Expense Increase

Operating and commercial expenses edged higher in 2025 as the company ramped up launch preparations for Zepzelca and other assets. Management signaled that commercial spending is likely to grow about 30% over the next two years, which could temporarily squeeze margins as new launches scale.

Forward-Looking Guidance and Key Milestones

Looking ahead to 2026, PharmaMar expects continued top-line growth, supported by potential European approval and launch of Zepzelca and rising U.S. and EU royalties. While commercial spending is set to climb around 30% and R&D should hold near €95 million, investors will be watching landmark readouts such as LAGOON in late 2026 and subsequent filing opportunities.

PharmaMar’s earnings call painted a picture of a company balancing robust growth, expanding margins and a busy catalyst calendar against real competitive and pricing risks. If management can execute on European Zepzelca launches, manage generic pressure on Yondelis, and deliver on pipeline milestones, the positive momentum of 2025 could extend into a multi-year growth story.